MedTrace Logo

Complement-activating Anti-human Leucocyte Antigen Donor Specific Antibodies in Solid Organ Transplantation

NCT03438058 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7547

Last updated 2018-02-19

No results posted yet for this study

Summary

This project will involve a systematic literature review and meta-analysis of studies assessing the impact of complement-activating anti-Human Leukocyte Antigen (HLA) donor specific antibodies (DSA) on the allograft survival rate and on the rejection rate.

This meta-analysis will assess the role of complement activating anti-HLA DSAs across the entire transplant field including kidney, liver, lung and heart transplant recipient's studies.

Conditions

  • Organ Transplant Recipients

Interventions

OTHER

Graft survival and/or Rejection appearance

Sponsors & Collaborators

  • Paris Translational Research Center for Organ Transplantation

    lead OTHER

Principal Investigators

  • Carmen Lefaucheur, PhD · Paris Translational Research Center for Organ Transplantation

  • Alexandre Loupy, PhD · Paris Translational Research Center for Organ Transplantation

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2018-01-31
Completion
2018-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03438058 on ClinicalTrials.gov